Abstract 377P
Background
Human papillomavirus (HPV) associated oropharyngeal squamous cell cancers (OPSCC) are known to have better treatment response and outcome compared with HPV -negative ones. Testing for p16 expression is used as a surrogate for HPV testing. While p16- positive tumours comprise of majority of OPSCC in Western population, p16 -positive tumours in Asian population have remained low.
Methods
Data of Indian patients treated at a single institute between 2016 -2023 was ambispectively analyzed for rate of p16 positivity and clinical outcomes. Staining of ≥70% was considered positive for p16. Data entry and analysis was done using IBM SPSS Statistics v21.0.
Results
Between February 2016 – June 2023, 114 patients were treated, of which 106 had SCC. Majority subsites were tonsil (50, 47.2%), base of tongue (30, 28.3%), and soft palate (15, 14.2%). Testing for p16 was done in 66 patients (62%), of which 19 were p16-positive. Smoking history was noted in 36 patients (34%). Treatment modalities were CTRT for 74 patients (69.8%) and RT alone for 32 (30.2%). IMRT was utilized for majority patients (97, 91.5%). Chemotherapeutic agents were cisplatin for 61 (82.4%, 6 (9.8%) shifted to carboplatin) [3 weekly-9, weekly-52], carboplatin 11 (15%) and cetuximab 2 (3%). Treatment was completed by 101 patients (95.3%) [2 discontinued treatment, 3 died before treatment completion due to non-oncologic causes]. At 3 months, response assessment was done for 94 patients, of which 74 (78.7%) had complete response [14/15 (93.3%) p16-positive, 31/41 (75.6%) p16-negative]; 7 patients (7.4%) had incomplete response while 13 (13.8%) progressed. At median follow-up of 23 months (IQR 11–42); 90 patients were alive, 72 (71.3%) had disease under control. Relapse was seen in 9 patients (p16-positive – 0, p16-negative – 4, untested – 5). Median progression free survival was 17 months (IQR 5-37 months).
Conclusions
While p16 positivity amongst Indian OPSCC patients remains lower than Western counterparts, p16 -positive OPSCC have shown favorable response rates in Indian patients. Association of p16 positivity with improved response rates and fewer relapses in the Indian population warrants investigation in a larger randomized trial.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Amrita Cancer Institute.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
87TiP - Phase I expansion study of the tissue factor (TF)–targeting antibody-drug conjugate (ADC) XB002 as a single-agent and combination therapy in patients with advanced solid tumors (JEWEL-101)
Presenter: Mustafa Syed
Session: Poster Display
Resources:
Abstract
88TiP - A phase Ib study of HMBD-001, a monoclonal antibody targeting HER3, with or without chemotherapy in patients with genetic aberrations in HER3 signaling
Presenter: Nick Pavlakis
Session: Poster Display
Resources:
Abstract
93P - Efficacy and safety of fruquintinib (F) + best supportive care (BSC) vs placebo (P) + BSC in refractory metastatic colorectal cancer (mCRC): Asian vs non-Asian outcomes in FRESCO-2
Presenter: Daisuke Kotani
Session: Poster Display
Resources:
Abstract
94P - Sidedness-dependent prognostic impact of gene alterations in metastatic colorectal cancer in the nationwide cancer genome screening project in Japan (SCRUM-Japan GI-SCREEN)
Presenter: Takeshi Kajiwara
Session: Poster Display
Resources:
Abstract
95P - Interim results of a prospective randomized controlled study to compare the clinical outcomes of total neoadjuvant therapy vs long course chemoradiotherapy in locally advanced carcinoma rectum
Presenter: Sandip Barik
Session: Poster Display
Resources:
Abstract
96P - Tyrosine kinase inhibitor (TKI) plus PD-1 blockade in TKI-responsive MSS/pMMR metastatic colorectal adenocarcinoma (mCRC): Updated results of TRAP study
Presenter: Jingdong Zhang
Session: Poster Display
Resources:
Abstract
97P - Asian subgroup analysis of the phase III LEAP-017 trial of lenvatinib plus pembrolizumab vs standard-of-care in previously treated metastatic colorectal cancer (mCRC)
Presenter: Rui-Hua Xu
Session: Poster Display
Resources:
Abstract
98P - Real clinical impact of postoperative surgical complications after colon cancer surgery
Presenter: Toru Aoyama
Session: Poster Display
Resources:
Abstract
99P - Extended lymphadenectomy may not be necessary for MSI-H colon cancer patients after immunotherapy
Presenter: Rongxin Zhang
Session: Poster Display
Resources:
Abstract
100P - Identification of phenomic data in the pathogenesis of colorectal cancer: A UK biobank data analysis
Presenter: Shirin Hui Tan
Session: Poster Display
Resources:
Abstract